GET DAILY SIGNALSZoetis (ZTS): Can the Stock Reach the $95 Target After Recent Volatility?
Key Takeaways
- The central target discussed here is $95, the arithmetic mean of the eight verified analyst price targets that sit above Zoetis's latest price of $82.99.
- Twelve current analyst targets were reviewed, ranging from $74 to $115; the overall mean of all twelve is about $90, which fell below the 10% threshold above the price, so the above-price average of $95 is used as the central target.
- Reaching $95 would require a roughly 14% advance from the November 3, 2026 close of $82.99 — a substantial but not extreme move.
- Supporting factors include a dominant animal-health franchise, a diversified companion-and-livestock mix, a low-teens P/E ratio, and new products such as the osteoarthritis therapy Lenivia.
- The biggest risks are softer U.S. companion-animal demand, generic competition in products like Convenia and Cerenia, safety scrutiny around Librela, and repeated guidance cuts.
- The consensus rating is a Hold, but disagreement is wide — for example, J.P. Morgan holds a Buy with a $115 target while Goldman Sachs initiated at Hold with a $74 target.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for Zoetis.
- You can also explore Trending AI Robots to see AI-driven strategies monitoring names like ZTS.
Analyst Targets: A Divided Outlook
This review covers twelve recent, individually attributable analyst price targets. With the stock having pulled back sharply, those targets now cluster below previous highs and span $74 to $115. The full average across all twelve comes to roughly $90, or about 8% above the latest price. Because that falls short of a meaningful threshold, the central target used here is the average of the eight targets still above the current price, which lands near $95. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Sentiment remains split. J.P. Morgan ($115, Buy, October 2026) and Citi ($96, Buy) stay constructive, while Goldman Sachs ($74, Hold, initiation) and Jefferies (downgraded to Hold, $83, October 2026) take a more cautious stance. Morgan Stanley trimmed its target to $82 and UBS to $85. The recurring theme in the downgrades centers on U.S. companion-animal demand softening more quickly than anticipated.
Current Position and the Road to $95
Zoetis closed at $82.99 on November 3, 2026, with a market value near $34 billion. Reaching $95 would mean a gain of about 14%, a sizable but realistic step given the 52-week range of $68.77 to $144.83. The route would hinge mainly on stabilizing U.S. companion-animal sales—pressured by price sensitivity, fewer veterinary visits, and generics—and meeting 2026 guidance that Wall Street has already lowered several times.
Factors That Could Support a Move Higher
Zoetis holds a clear leadership position, with revenue split roughly 65% companion animal and 35% livestock. Valuation looks reasonable at a trailing P/E near 13, alongside a dividend yield close to 2.5% and a track record of buybacks. Fresh launches such as Lenivia, a long-acting osteoarthritis antibody approved in the UK, plus solid international and livestock trends give bulls reason to expect earnings stabilization. If the November 5 results show companion-animal volumes finding a bottom, the compressed valuation could support a re-rating toward the $95 area.
Risks That Could Keep the Stock Below Target
The challenges are tangible. Zoetis has trimmed full-year guidance more than once, and its second-quarter 2026 adjusted EPS range of roughly $6.15 to $6.25 sat well below the Street’s earlier consensus near $6.87. U.S. companion-animal sales have declined, generic competition is pressuring key products, and Librela-related safety questions have led to securities litigation. Should demand weakness continue or competition intensify, further target reductions—such as Jefferies’ drop from $103 to $83—could hold the shares below $95.
Technical Levels Worth Watching
Technically, Zoetis has recovered from its 52-week low near $68.77 into the low $80s, making the $80 round number a potential nearby support level, with $74–$75 below it. On the upside, the $90 to $95 zone forms the first notable resistance cluster, followed by the psychological $100 mark. The stock remains well below its prior peak of $144.83, so any sustained push toward $95 would likely need a lasting trend shift rather than a brief rebound.
Time Horizon and Key Items to Monitor
Analyst price targets generally reflect a roughly 12-month horizon, though individual firms differ. The immediate catalyst is the November 5, 2026 earnings report, which should clarify companion-animal trends and any updated guidance. Investors will also want to track further analyst revisions, commentary on Librela and Lenivia, generic competition affecting Convenia and Cerenia, and broader consumer-spending signals that influence veterinary demand.
Using AI Daily Buy/Sell Signals in My Process
In my own analysis of names like ZTS, I often review Tickeron’s AI Daily Buy/Sell Signals to track how technical patterns and market conditions evolve in real time. The tool generates Buy, Sell, or Hold signals across thousands of stocks and ETFs, which helps me cross-check my own views on volatile holdings without replacing deeper fundamental work. It has become a regular part of staying on top of shifting trends for this type of name.
Final Assessment
Can Zoetis reach $95? The question is fair but far from certain. The $95 central target draws only from the analyst estimates still above today’s price, while the wider $74 to $115 range reflects real differences of opinion on the company’s path. A 14% advance is possible if companion-animal demand stabilizes and the modest valuation re-rates, yet ongoing guidance cuts, generics, and Librela-related litigation remain meaningful hurdles. The November earnings report and any follow-up analyst changes will provide the clearest signal on whether $95 represents a realistic next step.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZTS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ZTS turned positive on October 06, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on ZTS as a result. In 45 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
ZTS moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 142 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 98 of 188 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ZTS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ZTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.894) is normal, around the industry mean (8.179). P/E Ratio (13.538) is within average values for comparable stocks, (-0.806). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.202). Dividend Yield (0.026) settles around the average of (0.046) among similar stocks. P/S Ratio (3.299) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pet medication company
Industry PharmaceuticalsGeneric
Advertisement